Zobrazeno 1 - 1
of 1
pro vyhledávání: '"59"'
Autor:
Joel Lexchin
Publikováno v:
PLoS ONE, Vol 15, Iss 11, p e0240966 (2020)
PLoS ONE
PLoS ONE
IntroductionStudies of the delay between when companies file a New Drug Submission (NDS) and when drugs reach Canadian patients typically focus on the time in the regulatory review process and do not analyze the time between when approval is granted